Individuals with resistant schizophrenia

Declined to participate or excluded

Informed consent
Baseline investigations

RANDOMIZATION

ARM 1
Minocycline 200 mg/d (N=75)

ARM 2
Placebo (N=75)

Blinded Clinical assessment: week 0, week 6, week 12 and week 16

Primary outcome: Change in mean PANSS score between baseline and week 8

Secondary outcome: Change in negative symptom domain; Change in CGI score; Change in functioning; Adverse events

Figure 1. Adjunctive minocycline versus placebo: A trial flow diagram